Related Experiment Video
Updated: Jul 29, 2026
11:29
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Consolidative 32P after second-look laparotomy for ovarian carcinoma
K S Condra1, W M Mendenhall, L S Morgan
1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville 32610-0385, USA.
Radiation Oncology Investigations
|May 8, 1998
Summary
Consolidative 32P phosphorus therapy after surgery improved cancer control and survival rates in patients with advanced ovarian cancer. This treatment showed a low risk of severe complications, making it a viable option for reducing recurrence.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Second-look laparotomy is used to assess residual disease after chemotherapy.
- Consolidative 32P (radioactive phosphorus) is a potential treatment option post-surgery.
Purpose of the Study:
- To evaluate the efficacy and safety of consolidative 32P after second-look laparotomy in ovarian cancer patients.
- To determine the impact of 32P on local control and overall survival.
Main Methods:
- Retrospective analysis of 43 ovarian cancer patients treated with consolidative 32P post-chemotherapy and second-look laparotomy.
- Follow-up for a median of 7.7 years to assess disease control and survival rates.
- Multivariate analysis to identify factors influencing outcomes.
Main Results:
- 5-year local control rates were 65% overall and 69% for patients with negative second-look laparotomy.
- 5-year survival rates were 78% overall and 81% for patients with negative second-look laparotomy.
- Presence of tumor at second-look laparotomy significantly impacted local control and survival.
Conclusions:
- Consolidative 32P is associated with reduced recurrence risk and improved survival after negative second-look laparotomy in ovarian cancer.
- The treatment demonstrates a low incidence of severe acute and late complications.
- 32P therapy represents a valuable option for improving outcomes in selected ovarian cancer patients.
